Biomea Fusion Clinical Trial Data
Biomea Fusion announced topline results from its Phase 1 GLP-131 clinical trial evaluating BMF-650, an investigational oral small molecule GLP-1 receptor agonist. The study focused on healthy overweight or obese adult participants over a 4-week period to assess safety and efficacy. The company hosted a conference call and provided an investor presentation to discuss the findings and the potential of BMF-650 in treating obesity and metabolic diseases.